MIAMI, Oct. 06, 2026 (GLOBE NEWSWIRE) --

迈阿密，2026年10月6日（环球新闻社）——

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO)

泰洛米尔制药公司（纳斯达克股票代码：TELO）

, a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced an approximately $5.6 million private investment in public equity (PIPE) financing through the issuance of common stock, without any accompanying investor warrants or convertible securities..

，一家处于临床阶段的生物技术公司，致力于开发针对癌症表观遗传和代谢驱动因素的小分子疗法，今日宣布通过发行普通股完成约560万美元的私募股权投资（PIPE）融资，未附带任何投资者认股权证或可转换证券。

The financing includes an additional $1.0 million investment from billionaire entrepreneur and existing significant shareholder John Paul DeJoria, co-founder of John Paul Mitchell Systems and Patrón Spirits. Other existing shareholders and new investors also participated in the financing.

此次融资包括亿万富翁企业家、现有重要股东约翰·保罗·德乔里亚额外投资的100万美元，他是约翰·保罗·米切尔系统公司和Patrón Spirits公司的联合创始人。其他现有股东和新投资者也参与了此次融资。

DeJoria most recently reported beneficial ownership of approximately 3.55 million shares, representing approximately 5.0% of Telomir’s outstanding common stock. His additional $1.0 million investment further increases his investment in Telomir as the Company advances its lead program into clinical development..

德乔里亚最近报告称，其受益所有权约为355万股，约占Telomir已发行普通股的5.0%。随着该公司将其主导项目推进至临床开发阶段，他额外投资的100万美元进一步增加了其在Telomir的投资。

“I have always looked for opportunities that can do the greatest good for the greatest number of people, and that is part of what attracted me to Telomir,” said John Paul DeJoria. “Cancer continues to take an enormous toll on patients and families, and there remains a need for new approaches that can potentially improve the way we treat this disease.

“我一直寻求能够为最多数人带来最大福祉的机会，这也是吸引我加入Telomir的原因之一。”约翰·保罗·迪乔里亚表示，“癌症继续给患者和家庭带来巨大负担，我们仍然需要新的方法来 potentially 改善这种疾病的治疗方式。”

Telomir is pursuing a different scientific approach, and with the Company now moving into human clinical trials, I am pleased to increase my investment and support the team as they work to determine what Telomir-Zn may be able to do for patients.”.

Telomir 正在采取一种不同的科学方法，随着公司目前进入人体临床试验阶段，我很高兴增加投资，支持团队努力确定 Telomir-Zn 能为患者带来何种益处。

Alexander Capital, L.P. acted as placement agent for the financing. The Company expects to receive aggregate gross proceeds of approximately $5.6 million, before deducting placement agent fees and other offering expenses.

Alexander Capital, L.P. 担任了此次融资的配售代理。公司预计在扣除配售代理费及其他发行费用前，将获得总计约560万美元的毛收益。

Financing Terms

融资条款

Under the terms of the financing, Telomir issued 4,843,300 shares of common stock at a purchase price of $1.16 per share, representing a 5% discount to the applicable 10-day volume-weighted average price (VWAP). The financing resulted in aggregate gross proceeds to the Company of approximately $5.6 million, before deducting placement agent fees and other offering expenses..

根据融资条款，Telomir 以每股 1.16 美元的价格发行了 4,843,300 股普通股，该价格较适用的 10 日成交量加权平均价（VWAP）折让 5%。此次融资为公司带来的总毛收益约为 560 万美元，未扣除配售代理费及其他发行费用。

Investors in the financing purchased common stock at a fixed price, with no accompanying investor warrants, convertible securities, or variable-price or reset features.

融资投资者以固定价格购买普通股，不附带任何认股权证、可转换证券或可变价格或重置条款。

The securities were issued in a private placement. Telomir has agreed to file a registration statement with the U.S. Securities and Exchange Commission covering the resale of the shares issued in the financing, subject to the terms of the Registration Rights Agreement.

该等证券系通过私募方式发行。Telomir 已同意根据《注册权协议》的条款，向美国证券交易委员会提交一份注册声明，以涵盖此次融资中所发行股份的转售事宜。

The Company intends to use the net proceeds primarily to support the clinical development of Telomir-Zn, including its Phase 1/2 clinical program in advanced or metastatic triple-negative breast cancer (TNBC), as well as for working capital and general corporate purposes.

本公司拟将净收益主要用于支持Telomir-Zn的临床开发，包括其在晚期或转移性三阴性乳腺癌（TNBC）中的1/2期临床计划，以及用于营运资金和一般公司用途。

“We have been very deliberate about how and when we access the capital markets,” said

“我们对于如何以及何时进入资本市场一直非常审慎，”

Erez Aminov, Chairman and CEO of Telomir

Erez Aminov，Telomir 董事长兼首席执行官

. “Our strategy is to raise capital around meaningful milestones, deploy it toward value-driving objectives and progressively de-risk the program, while remaining mindful of our existing shareholders. As Telomir enters clinical development, our focus is on execution: deploying this capital efficiently to advance Telomir-Zn through its Phase 1/2 clinical program, generate meaningful human data and position the Company strongly for the milestones ahead.”.

“我们的战略是围绕具有实质意义的里程碑筹集资金，将资金投入到能够驱动价值的目标上，并逐步降低项目风险，同时充分顾及现有股东的利益。随着Telomir进入临床开发阶段，我们的重心在于执行：高效部署资金，推动Telomir-Zn顺利通过1/2期临床研究计划，生成具有实质意义的人体数据，并为实现后续里程碑奠定坚实基础。”

Strengthening Telomir’s Position for Clinical Execution

加强Telomir在临床执行方面的地位

The financing comes as Telomir advances Telomir-Zn, its lead investigational oral small molecule, into human clinical evaluation. The U.S. Food and Drug Administration has cleared Telomir’s Investigational New Drug (IND) application for Telomir-Zn, enabling the Company to proceed with its first-in-human Phase 1/2 clinical trial in patients with advanced or metastatic TNBC..

此次融资正值Telomir推进其首要 investigational 口服小分子药物Telomir-Zn进入人体临床评估阶段。美国食品药品监督管理局已批准Telomir关于Telomir-Zn的新药临床试验（IND）申请，使公司能够针对晚期或转移性三阴性乳腺癌（TNBC）患者开展首次人体I/2期临床试验。

TNBC is an aggressive form of breast cancer defined by the absence of three common therapeutic targets, estrogen receptors, progesterone receptors, and HER2, limiting the applicability of many targeted treatments used in other forms of breast cancer. Patients with advanced or metastatic disease continue to face a significant need for additional treatment options..

三阴性乳腺癌（TNBC）是一种侵袭性乳腺癌，其特征是缺乏三种常见的治疗靶点——雌激素受体、孕激素受体和HER2，这限制了许多用于其他类型乳腺癌的靶向治疗的适用性。晚期或转移性患者仍然迫切需要对更多治疗选择的需求。

The multicenter, open-label Phase 1/2 study is designed to move Telomir-Zn from initial human dosing through dose selection and into an efficacy-focused expansion. The Phase 1 portion will evaluate safety, tolerability, and dose selection while also assessing pharmacodynamic biomarkers and preliminary signals of antitumor activity.

这项多中心、开放标签的1/2期研究旨在推动Telomir-Zn从初始人体给药阶段，经过剂量选择，进入以疗效为重点的扩展阶段。1期部分将评估安全性、耐受性和剂量选择，同时评估药效学生物标志物和抗肿瘤活性的初步信号。

The Phase 2 expansion is designed to build on those findings with a greater focus on efficacy, providing an initial clinical proof-of-concept assessment of Telomir-Zn in advanced or metastatic TNBC..

二期扩展研究旨在基于这些发现，更加侧重于疗效评估，对Telomir-Zn在晚期或转移性三阴性乳腺癌（TNBC）中的临床应用进行初步的概念验证评估。

A New Epigenetic Approach to Treating Cancer

治疗癌症的新表观遗传学方法

Telomir-Zn is being developed as a potentially first-in-class oral epigenetic therapy designed to modulate intracellular metal homeostasis, particularly iron and copper, and influence gene-control pathways implicated in cancer. Preclinical studies have demonstrated inhibition of multiple iron-dependent histone demethylases (KDMs), supporting the Company’s hypothesis that Telomir-Zn may help restore more normal epigenetic regulation and potentially reactivate tumor-suppressor pathways that cancer has silenced..

Telomir-Zn 正在被开发为一种潜在的首创口服表观遗传疗法，旨在调节细胞内金属稳态（尤其是铁和铜），并影响与癌症相关的基因调控通路。临床前研究已证明其对多种铁依赖性组蛋白去甲基化酶（KDMs）具有抑制作用，这支持了公司的假设，即 Telomir-Zn 可能有助于恢复更正常的表观遗传调控，并可能重新激活被癌症沉默的肿瘤抑制通路。

About Telomir Pharmaceuticals

关于 Telomir 制药公司

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The Company’s lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation and has received Investigational New Drug clearance from the U.S.

Telomir Pharmaceuticals, Inc.（纳斯达克股票代码：TELO）是一家处于临床阶段的生物技术公司，致力于开发靶向与癌症相关的表观遗传和代谢通路的小分子疗法。公司的核心项目 Telomir-Zn 旨在调节细胞内金属稳态和表观遗传调控，并已获得美国食品药品监督管理局的新药临床试验批准。

Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer. For more information, please visit .

向美国食品药品监督管理局申请开展针对晚期或转移性三阴性乳腺癌患者的1/2期临床试验。欲了解更多信息，请访问。

https://telomirpharma.com/

https://telomirpharma.com/

.

。

Forward-Looking Statements

前瞻性陈述

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target,” and other words of similar meaning, although not all forward-looking statements include these words..

本新闻稿包含1995年《私人证券诉讼改革法案》所定义的“前瞻性陈述”。这些前瞻性陈述通常可以通过使用“预期”、“预计”、“计划”、“能够”、“可能”、“将会”、“可以”、“将”、“相信”、“估计”、“预测”、“目标”、“规划”、“指引”、“潜在”、“打算”、“寻求”、“瞄准”等词语以及具有类似含义的其他词语来识别，尽管并非所有前瞻性陈述都包含这些词语。

Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, clinical utility, market opportunity, and future development of Telomir-1 (Telomir-Zn) and the Company’s other product candidates.

前瞻性陈述可能包括但不限于关于Telomir-1（Telomir-Zn）及公司其他候选产品的治疗潜力、作用机制、开发计划、监管路径、安全性特征、临床应用价值、市场机会和未来发展的陈述。

Forward-looking statements may also include statements regarding the anticipated closing of the financing described herein, the expected proceeds from and intended use of such proceeds, the significance of the published preclinical findings, the relevance of such findings to the Company’s oncology development programs, the advancement of the Company’s Phase 1/2 TNBC clinical trial, and the potential applicability of Telomir-Zn across multiple disease areas..

前瞻性陈述还可能包括有关以下内容的陈述：本文所述融资交易的预期完成、预期募集资金及其拟用途、已发表临床前发现的重要性、此类发现与公司肿瘤学开发项目的相关性、公司三阴性乳腺癌（TNBC）1/2期临床试验的进展，以及Telomir-Zn在多个疾病领域的潜在适用性。

These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

这些前瞻性陈述基于当前的预期、估计、预测和推测，以及管理层的信念和假设，并受重大风险和不确定性的影响，这些因素可能导致实际结果与此类陈述中明示或暗示的结果存在重大差异。

These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s other filings with the U.S.

这些风险和不确定性包括但不限于：与临床前和临床开发相关的风险、获得监管批准的能力、未来研究的结果、对第三方的依赖、知识产权保护、融资需求、市场状况，以及公司10-K表格年度报告和公司向美国提交的其他文件中“风险因素”标题下确定的其他风险。

Securities and Exchange Commission (“SEC”)..

美国证券交易委员会（“SEC”）

Forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update or revise such statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

本新闻稿中包含的前瞻性陈述仅反映截至本新闻稿发布之日的情况，除非适用法律另有要求，公司不承担因新信息、未来事件或其他原因而更新或修订此类陈述的义务。

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at the SEC website and in the “Investors” section of our website, for a discussion of these and other risks and uncertainties..

我们提醒投资者不要过度依赖本新闻稿中包含的前瞻性陈述。我们鼓励您阅读我们在美国证券交易委员会（SEC）提交的文件，这些文件可在SEC网站以及我们公司网站的“投资者”部分获取，以了解对这些及其他风险和不确定性的讨论。

Private Placement Disclosure

私募配售披露

The securities described in this press release are being offered and sold in a private placement and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws..

本新闻稿中所述的证券正以私募方式发行和销售，且未根据经修订的《1933年证券法》（以下简称“《证券法》”）或适用的州证券法律进行注册。因此，除非依据生效的注册声明或符合《证券法》及适用州证券法律规定的注册要求豁免，否则不得在美国境内要约或出售该等证券。

The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission covering the resale of the shares of common stock issued in the private placement, subject to the terms and conditions of the applicable registration rights agreement.

公司已同意向美国证券交易委员会提交一份注册声明，涵盖私募发行中发行的普通股的转售事宜，但须遵守适用注册权协议的条款和条件。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction..

本新闻稿不构成出售任何证券的要约，也不构成购买任何证券的要约邀请；在任何司法管辖区，若在该等司法管辖区的证券法下，未经注册或资格认定即进行此类要约、邀请或销售属违法行为，则在该等司法管辖区内不得进行任何此类要约、邀请或销售。

Contact Information

联系方式

Krystina Quintana

克里斯蒂娜·金塔纳

Email: info@telomirpharma.com

邮箱：info@telomirpharma.com

Phone: (786) 396-6723

电话：(786) 396-6723